Thelansis

Hemophilia B Market Outlook Thelansis’s “Hemophilia B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hemophilia B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do intervie...

Hemophilia B Market Outlook Thelansis’s “Hemophilia B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hemophilia B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Hemophilia B Overview Hemophilia B is an uncommon congenital blood disorder characterized by a clotting factor IX (FIX) deficiency, resulting in spontaneous bleeding episodes, particularly in joints, and delayed blood clotting during external bleeding incidents. Repeated joint bleeding can lead to long-term joint deterioration, physical limitations, the necessity for joint replacements, chronic pain, and a diminished quality of life (QoL). The level of circulating FIX...

 Hemophilia B is an uncommon congenital blood disorder characterized by a clotting factor IX (FIX) deficiency, resulting in spontaneous bleeding episodes, particularly in joints, and delayed blood clotting during external bleeding incidents. Repeated joint bleeding can lead to long-term joint deterioration, physical limitations, the necessity for joint replacements, chronic pain, and a diminished quality of life (QoL). The level of circulating FIX determines the severity of Hemophilia B (HB). The treatment approach revolves around FIX replacement therapy, which can be administered either preventively to avert bleeding episodes or reactively after a bleeding episode, known as "on-demand" treatment. Prophylactic FIX therapy is regarded as the standard of care for patients with severe and moderately severe HB. FIX is administered through intravenous injections in either standard half-life (SHL) or extended half-life (EHL) treatments every 2–3 or 7–14 days. However, the frequent ...